TORL Biotherapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, TORL Biotherapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 5 currently recruiting early-phase tilt upper quartile by trial count

TORL Biotherapeutics: 8 sponsored US clinical trials, 5 recruiting.

TORL Biotherapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 5 trials.

Upper-quartile sponsor footprint

TORL Biotherapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

NCT07439653
RECRUITING Phase 1

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

NCT07322094
RECRUITING Phase 2

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775
RECRUITING Phase 1

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

NCT06005740
RECRUITING Phase 1

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

NCT05103683
ACTIVE NOT RECRUITING Phase 1

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

NCT05948826
ACTIVE NOT RECRUITING Phase 1

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

NCT05156866
ACTIVE NOT RECRUITING Phase 1

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

NCT05159440

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1

Therapeutic Areas

Advanced Solid Tumor 5
Pancreas Cancer 2
Gastric Cancer 2
Gastroesophageal Junction Adenocarcinoma 2
Primary Peritoneal 1
Fallopian Tube Cancers 1
FIGO Stage III and IV Ovarian Cancer 1
Endometrioid Ovarian Cancer 1
Fallopian Tube Cancer 1
Primary Peritoneal Cancer 1

What is open in the TORL Biotherapeutics pipeline

5 recruiting of 8 indexed (63% open).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumor (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

TORL Biotherapeutics: open-pipeline peers nationwide

Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.

TORL Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share TORL BiotherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Canadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care SystemNurix Therapeutics
TORL Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

TORL Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 63% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this TORL Biotherapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of TORL Biotherapeutics or any single study.

  • 5 of TORL Biotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Solid Tumor is the condition TORL Biotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. TORL Biotherapeutics pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.